<SEC-DOCUMENT>0001140361-24-049432.txt : 20241213
<SEC-HEADER>0001140361-24-049432.hdr.sgml : 20241213
<ACCEPTANCE-DATETIME>20241213161111
ACCESSION NUMBER:		0001140361-24-049432
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20241213
DATE AS OF CHANGE:		20241213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cartesian Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-283806
		FILM NUMBER:		241548446

	BUSINESS ADDRESS:	
		STREET 1:		7495 NEW HORIZON WAY
		CITY:			FREDERICK
		STATE:			MD
		ZIP:			21703
		BUSINESS PHONE:		301-348-8698

	MAIL ADDRESS:	
		STREET 1:		7495 NEW HORIZON WAY
		CITY:			FREDERICK
		STATE:			MD
		ZIP:			21703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SELECTA BIOSCIENCES INC
		DATE OF NAME CHANGE:	20090109
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>ny20039376x3_s3.htm
<DESCRIPTION>S-3
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.11.1.5268
         Copyright 1995 - 2024 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 540pt;"><a name="ny20039376x3_s3_100-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 540pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 25pt; text-align: center;">As filed with the Securities and Exchange Commission on December&#160;13, 2024 </div><div class="BRDSX_regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 1pt; text-align: right;">Registration No. 333-&#8195;&#8195;&#8195;&#8195; </div></div></div><div class="BRDSX_block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="BRDSX_block-main" style="width: 540pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 8pt; text-align: center;">UNITED STATES <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">Washington, D.C. 20549 </font></div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 1.75pt;"> </div></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 5pt; text-align: center;">FORM S-3 <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">REGISTRATION STATEMENT <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 11pt;"><font style="font-size: 11pt; font-style: italic;">UNDER </font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 11pt;"><font style="font-size: 11pt; font-style: italic;">THE SECURITIES ACT OF 1933</font><font style="font-size: 11pt; font-weight: normal;"> </font></div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 1.75pt;"> </div></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 5.5pt; text-align: center;">CARTESIAN THERAPEUTICS, INC. <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">(Exact name of registrant as specified in its charter) </font></div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 1.75pt;"> </div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 540pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 264pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 264pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">26-1622110 </div></td></tr><tr><td style="width: 264pt; padding-top: 1.02pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(State or other jurisdiction of<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">incorporation or organization)</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 264pt; padding-top: 1.02pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(I.R.S. Employer<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Identification Number)</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 3pt; text-align: center;">7495 New Horizon Way <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Frederick, Maryland 21703 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(301) 348-8698 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Address, including zip code and telephone number, including area code, of registrant&#8217;s principal executive offices) </div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 1.75pt;"> </div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 5pt; text-align: center;">Carsten Brunn, Ph.D. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">President and Chief Executive Officer <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">7495 New Horizon Way <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Frederick, Maryland 21703 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(301) 348-8698 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Name, address, including zip code and telephone number, including area code, of agent for service) </div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 1.75pt;"> </div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-style: italic; font-weight: bold; margin-top: 5pt; text-align: center;">With copies to: <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 3pt; text-align: center;">Brian K. Rosenzweig <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sarah C. Griffiths <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Covington &amp; Burling LLP <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">One International Place, Suite 1020 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Boston, Massachusetts 02110 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">(617) 603-8805 </div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 1.75pt;"> </div></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Approximate date of commencement of proposed sale to the public:<font style="font-weight: normal;"> From time to time after this registration statement becomes effective. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the only securities being registered on this Form&#160;are being offered pursuant to dividend or interest reinvestment plans, please check the following box: <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of the securities being registered on this Form&#160;are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: &#x2612; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 588pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 24pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 60pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 240pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Large accelerated filer</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 9.5pt;">&#x2610;</font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accelerated filer</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612; </div></td></tr><tr><td style="width: 240pt; padding-top: 0.02pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-accelerated filer</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.34pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 9.5pt;">&#x2610;</font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.02pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Smaller reporting company</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.02pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612; </div></td></tr><tr><td style="width: 240pt; padding-top: 0.02pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.02pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.02pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Emerging growth company</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.34pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 9.5pt;">&#x2610;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 24pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 60pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of Securities Act. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section&#160;8(a) may determine.</div></div><div class="BRDSX_block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 456pt;"><a name="ny20039376x3_s3_101-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 456pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><div style="font-family: Arial, Helvetica, sans-serif; text-align: left; margin-bottom: 12pt;">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </div>SUBJECT TO COMPLETION, DATED DECEMBER 13, 2024<font style="color: #000000;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">PROSPECTUS </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">6,251,150 Shares </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.25pt; text-align: center;"><img style="height: 84px; width: 278px;" src="logo_cartesian.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Cartesian Therapeutics, Inc. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">Common Stock <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offered by the Selling Stockholders </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein, or the Selling Stockholders, of up to (i) 5,813,223 shares, or the Private Placement Common Shares, of our common stock, par value $0.0001 per share, or the Common Stock, and (ii) 437,927 shares of Common Stock, or the Private Placement Conversion Shares, issuable upon the conversion of 437,927 shares, or the Private Placement Preferred Shares, of Series&#160;B Non-Voting Convertible Preferred Stock, par value $0.0001, or the Series&#160;B Preferred Stock. Each share of Series&#160;B Preferred Stock is convertible into one share of Common Stock, subject to certain beneficial ownership limitations. The shares of Common Stock registered by the registration statement of which this prospectus forms a part are referred to herein as the &#8220;Resale Shares.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Private Placement Common Shares and the Private Placement Preferred Shares were issued and sold to certain institutional and accredited investors in a private placement, or the Private Placement, which closed on July&#160;3, 2024. We are not selling any Resale Shares under this prospectus and will not receive any of the proceeds from the sale or other disposition of Resale Shares by the Selling Stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the over-the-counter market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading &#8220;<font style="font-style: italic;">Plan of Distribution</font>&#8221; elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise dispose of their Resale Shares hereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should carefully read this prospectus and any applicable prospectus supplement before you invest in any of the securities being offered. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our Common Stock is traded on the Nasdaq Global Market under the symbol &#8220;RNAC.&#8221; On December&#160;12, 2024, the last reported sale price for our Common Stock was $20.12 per share. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in our securities involves a high degree of risk. Before investing in our securities, you should carefully consider the risks and uncertainties described under the caption &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; beginning on page <a href="#tRSF">9</a> of this prospectus and any similar section contained in the applicable prospectus supplement and in any free writing prospectus we have authorized for use in connection with a specific offering, and under similar headings in the documents incorporated by reference into this prospectus.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.<font style="font-weight: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; text-align: center;">The date of this prospectus is &#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;.</div></div></div></div>
<!--End Page 2-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_102-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS </div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 432pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 432pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tABT">ABOUT THIS PROSPECTUS<font style="padding-left: 4.33pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tABT"><font style="padding-left: 5pt;">1</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCNR">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS<font style="padding-left: 0.2pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCNR"><font style="padding-left: 5pt;">2</font> </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">WHERE YOU CAN FIND MORE INFORMATION<font style="padding-left: 3.84pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC"><font style="padding-left: 5pt;">4</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIBR">INCORPORATION BY REFERENCE<font style="padding-left: 1.57pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIBR"><font style="padding-left: 5pt;">5</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCOMP">THE COMPANY<font style="padding-left: 2.66pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCOMP"><font style="padding-left: 5pt;">6</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tOFF">THE OFFERING<font style="padding-left: 2.85pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tOFF"><font style="padding-left: 5pt;">7</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRSF">RISK FACTORS<font style="padding-left: 4.32pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRSF"><font style="padding-left: 5pt;">9</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP">USE OF PROCEEDS<font style="padding-left: 0.07pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP">10</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOC">DESCRIPTION OF CAPITAL STOCK<font style="padding-left: 3.11pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOC"><font style="padding-left: 0.37pt;">11</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSTO">SELLING STOCKHOLDERS<font style="padding-left: 0.82pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSTO">18</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD">PLAN OF DISTRIBUTION<font style="padding-left: 3.98pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD">24</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLMA">LEGAL MATTERS<font style="padding-left: 3.22pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLMA">27</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">EXPERTS<font style="padding-left: 1.77pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">28</a></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 432pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 3-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_103-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tABT"><!--Anchor--></a>ABOUT THIS PROSPECTUS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus is part of a registration statement that we filed with the SEC using a &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus contains information that you should consider when making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to provide you with information that is different from or in addition to the information contained in this prospectus or in any applicable prospectus supplement or in any related free writing prospectus prepared by or on behalf of us or to which we have referred you. Accordingly, neither we nor any Selling Stockholder takes any responsibility for, or can provide any assurance as to the reliability of, any information that others may give. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus titled &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">When we refer to &#8220;Cartesian,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; in this prospectus, we mean Cartesian Therapeutics, Inc. and its consolidated subsidiaries, unless otherwise specified. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus, including the documents incorporated by reference into this prospectus, also includes trademarks, tradenames and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and tradenames referred to in this prospectus may appear without the &#174; and &#8482; symbols. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 4-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_104-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCNR"><!--Anchor--></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus and the documents incorporated by reference herein contain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act, and Section&#160;21E of the Securities Exchange Act of&#160;1934, as amended, or the Exchange Act. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. Any statements about our management&#8217;s expectations, beliefs, plans, predictions, forecasts, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as &#8220;anticipate,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;continuing,&#8221; &#8220;ongoing,&#8221; &#8220;expects,&#8221; &#8220;intends&#8221; and similar words or phrases. All forward-looking statements, expressed or implied, included herewith are expressly qualified in their entirety by the cautionary statements contained or referred to herein. The inclusion of forward-looking information in this prospectus and the documents incorporated by reference herein should not be regarded as a representation by us or any other person that the future plans, estimates or expectations contemplated by us will be achieved. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Factors that may affect our results are disclosed in &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; beginning on page <a href="#tRSF">9</a> of this prospectus, and in the documents incorporated by reference into this prospectus and included or incorporated by reference in this prospectus. Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from those expressed include, but are not limited to, the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any future payouts under the contingent value right, or CVR, issued to our holders of record as of the close of business on December&#160;4, 2023; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to achieve the expected benefits or opportunities and related timing with respect to the Merger (as defined below) or to monetize any of our legacy assets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our future results of operations and financial position, business strategy, and the length of time that we believe our existing cash resources will fund our operations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our market size and our potential growth opportunities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our preclinical and clinical development activities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the efficacy and safety profile of our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential therapeutic benefits and economic value of our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing and results of preclinical studies and clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, current or potential bank failures; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">global events, including the ongoing conflicts between Russia and Ukraine and between Hamas and Israel and geopolitical tensions in China on our operations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential litigation related to the Merger instituted against us or our directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to prevent or minimize the effects of litigation and other contingencies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our status as a preclinical and development-stage company and our expectation to incur losses in the future, and the possibility that we never achieve or maintain profitability; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">uncertainties with respect to our ability to access future capital; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to maximize the value of our pipeline of product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our unproven approach to therapeutic intervention; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary regulatory approvals; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 5-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_104-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to continue to grow our manufacturing capabilities and resources; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to manufacture our product candidates, which in some cases are manufactured on a patient-by-patient basis; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to access manufacturing facilities and to receive or manufacture sufficient quantities of our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to maintain our existing or future collaborations or licenses and to seek new collaborations, licenses or partnerships; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impact of resurgence of the COVID-19 pandemic on our operations, the continuity of our business, including our preclinical studies and clinical trials, and general economic conditions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to protect and enforce our intellectual property rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">federal, state, and foreign regulatory requirements, including U.S. Food and Drug Administration, or FDA, regulation of our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to obtain and retain key executives and retain qualified personnel; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developments relating to our competitors and our industry, including the impact of government regulation. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The foregoing list may not contain all of the forward-looking statements made in this prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These forward-looking statements are only predictions based on our current expectations and projections about future events and are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; and elsewhere in this prospectus. Moreover, we operate in a competitive industry, and new risks emerge from time to time. It is not possible for the management of Cartesian to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements in this prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The forward-looking statements included in this prospectus are made only as of the date hereof. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We do not undertake any obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in expectations, except as required by law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should read this prospectus, the documents that have been filed as exhibits to the registration statement of which this prospectus forms a part, any accompanying prospectus supplement, and the documents incorporated by reference herein and therein with the understanding that the actual future results, levels of activity, performance, events and circumstances of Cartesian may be materially different from what is expected. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 6-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_104-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have filed with the SEC a registration statement on Form&#160;S-3 under the Securities Act with respect to the securities being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and our securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any document referred to are not necessarily complete, and in each instance, we refer you to the copy of the document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. You can read our SEC filings, including the registration statement, at the SEC&#8217;s website at www.sec.gov. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are subject to the information reporting requirements of the Exchange Act, and we file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information are available for review at the SEC&#8217;s website at www.sec.gov. We also maintain a website at www.cartesiantherapeutics.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Cartesian&#8217;s website and the information contained on, or that can be accessed through, such website are not deemed to be incorporated by reference in, and are not considered part of, this prospectus. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 7-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_105-incorp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tIBR"><!--Anchor--></a>INCORPORATION BY REFERENCE </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus the information in certain documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus. When we update the information contained in documents that have been incorporated by reference by making future filings with the SEC, the information incorporated by reference into this prospectus is considered to be automatically updated and superseded. In other words, in all cases, if you are considering whether to rely on information contained in this prospectus or information incorporated by reference into this prospectus, you should rely on the information contained in the document that was filed later. We incorporate by reference (other than any information furnished to, rather than filed with, the SEC, unless expressly stated otherwise therein) the documents listed below (File No. 001-37798 unless otherwise stated), which are considered to be a part of this prospectus: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000036/rnac-20231231.htm">March&#160;7, 2024</a>. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The information specifically incorporated by reference into our Annual Report on Form&#160;10-K from our Definitive Proxy Statement on Schedule 14A relating to our 2024 Annual Meeting of Stockholders, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000076/rnac-20240426.htm">April&#160;26, 2024</a>. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our Quarterly Reports on Form&#160;10-Q for the quarters ended March&#160;31, 2024, June&#160;30, 2024, and September&#160;30, 2024, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000082/rnac-20240331.htm">May&#160;8, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000102/rnac-20240630.htm">August&#160;8, 2024</a>, and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000124/rnac-20240930.htm">November&#160;7, 2024</a>, respectively. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our Current Reports on Form&#160;8-K (or amendments thereto) filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000030/rnac-20240117.htm">January&#160;19, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000114036124003407/ny20014884x4_8ka.htm">January&#160;23, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000114036124011282/ef20023144_8k.htm">March&#160;5, 2024</a> (except for Item&#160;7.01 and Exhibit&#160;99.1 thereto), <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000039/rnac-20240308.htm">March&#160;14, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000048/rnac-20240326.htm">March&#160;28, 2024</a> (except for Item&#160;7.01 and Exhibit&#160;99.1 thereto), <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000052/rnac-20240326.htm">April&#160;1, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000055/rnac-20240408.htm">April&#160;9, 2024</a> (except for Item&#160;7.01 and Exhibit&#160;99.1 thereto), <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000072/rnac-20240419.htm">April&#160;22, 2024,</a> <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000084/rnac-20240522.htm">May&#160;22, 2024</a> (except for Item&#160;7.01 and Exhibit&#160;99.1 thereto), <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000088/rnac-20240614.htm">June&#160;17, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000114036124032080/ef20031962_8k.htm">July&#160;2, 2024</a> (except for Item&#160;7.01 and Exhibits 99.1 and 99.2&#160;thereto), <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000108/rnac-20240920.htm">September&#160;23, 2024, </a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000110/rnac-20240925.htm">September&#160;26, 2024</a>, and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1453687/000145368724000143/rnac-20241203.htm">December&#160;3, 2024</a> (except for Item&#160;7.01&#160;and Exhibits 99.1 and 99.2 thereto). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The description of our Common Stock contained in our Registration Statement on Form&#160;8-A, filed with the SEC on June&#160;8, 2016, as amended by the description of our Common Stock contained in <a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368724000036/exhibit414descriptionofsec.htm">Exhibit 4.14</a> to our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed with the SEC on March&#160;7, 2024, and any further amendment or report filed with the SEC for the purpose of updating such description. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All reports and other documents we subsequently file with the SEC under Sections 13(a), 13(c), 14 or 15(d)&#160;of the Exchange Act until our offering is completed, including all such reports and other documents filed with the SEC after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to the effectiveness of such registration statement, will also be incorporated by reference into this prospectus and deemed to be part hereof (other than any information furnished to, rather than filed with, the SEC, unless expressly stated otherwise therein). The information contained in any such filing will be deemed to be a part of this prospectus commencing on the date on which the document is filed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or telephoning us at the following address: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Cartesian Therapeutics Inc. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7495 New Horizon Way <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Frederick, MD 21703 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(301) 348-8698 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any accompanying prospectus supplement. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 8-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_106-comp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCOMP"><!--Anchor--></a>THE COMPANY </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases. We leverage our proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell&#8217;s genetic material. Therefore, our mRNA cell therapies are distinguished by their capacity to be dosed repeatedly like conventional drugs, administered in an outpatient setting, and given without pre-treatment chemotherapy required with many conventional cell therapies. In an open-label Phase 2 clinical trial in patients with myasthenia gravis, or MG, a chronic autoimmune disease that causes disabling muscle weakness and fatigue, we observed that our lead product candidate, Descartes-08, generated a deep and durable clinical benefit, with all seven participants maintaining improvements in MG severity scales considered clinically meaningful by expert consensus at nine months, and five of the seven participants maintaining improvements in MG severity scales considered clinically meaningful by expert consensus at 12 months. Durability of response in MG is commonly measured over a period of 26 to 52 weeks, and maintenance of response over that period is considered durable. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our mRNA CAR-T modality is a personalized approach that collects a patient&#8217;s T-cells and uses mRNA to introduce a CAR into the cell. The CAR redirects the T-cells to target and destroy pathogenic self-reactive cells. Our mRNA in situ modality is designed to deliver mRNA into a patient&#8217;s lymph node to generate CAR-T cells and other proteins that target autoimmunity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We filed our certificate of incorporation with the Secretary of State of Delaware on December&#160;10, 2007. On&#160;November&#160;13, 2023, the Company and the Delaware corporation which, immediately prior to the Merger, was known as Cartesian Therapeutics, Inc., or Old Cartesian, entered into an Agreement and Plan of Merger, or the Merger Agreement, by and among the Company, Sakura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, or First Merger Sub, Sakura Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company, or Second Merger Sub, and Old Cartesian. Pursuant to the Merger Agreement, and simultaneously with execution thereof, (i) First Merger Sub merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corporation, or the First Step Surviving Corporation, and became a wholly owned subsidiary of the Company, or the First Merger, and (ii)&#160;immediately following the First Merger, Old Cartesian (as the First Step Surviving Corporation) merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving company, or the Surviving Company, and continued under the name &#8220;Cartesian Bio, LLC&#8221;, or the Second Merger and, together with the First Merger, the Merger. In connection with the Merger and pursuant to the Merger Agreement, the Company (which was known as Selecta Biosciences, Inc. until immediately prior to the Merger) changed its corporate name to Cartesian Therapeutics, Inc. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our principal executive offices are located at 7495 New Horizon Way, Frederick, MD 21703, and our telephone number is (301) 348-8698. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 9-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20039376x3_s3_107-summary_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tOFF"><!--Anchor--></a>THE OFFERING </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Shares Offered by the Selling Stockholders<font style="font-weight: normal; padding-left: 2.7pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">Up to (i) 5,813,223 shares of Common Stock and (ii)&#160;437,927 shares of Common Stock issuable upon the conversion of 437,927 shares of Series&#160;B Preferred Stock. </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Terms of the Offering <font style="font-weight: normal; padding-left: 1.03pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">The Selling Stockholders will determine when and how they will dispose of the shares of Common Stock and shares of Common Stock issuable upon conversion of Series&#160;B Preferred Stock registered under this prospectus for resale. </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Shares Outstanding<font style="font-weight: normal; padding-left: 2.14pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">As of September&#160;30, 2024, there were 23,896,525&#160;shares of our Common Stock, 166,341.592&#160;shares of Series&#160;A Preferred Stock and 437,927 shares of Series&#160;B Preferred Stock outstanding. </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of Proceeds<font style="font-weight: normal; padding-left: 0.83pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">We will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholders under this prospectus. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. See the section titled &#8220;<font style="font-style: italic;">Use of Proceeds</font>.&#8221; </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Risk Factors<font style="font-weight: normal; padding-left: 2.52pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">See the section titled &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our securities. </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Trading Markets and Ticker Symbols<font style="font-weight: normal; padding-left: 1.82pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">Our Common Stock is listed on the Nasdaq Global Market under the symbol &#8220;RNAC.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The number of shares of our Common Stock outstanding is based on 23,896,525 shares of our Common Stock outstanding as of September&#160;30, 2024. The number of shares outstanding as of September&#160;30, 2024 excludes as of such date: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">5,544,719 shares of Common Stock issuable upon the conversion of 166,341.592 shares of Series&#160;A Preferred Stock outstanding as of September&#160;30, 2024; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">437,927 shares of Common Stock issuable upon the conversion of 437,927 shares of Series&#160;B Preferred Stock outstanding as of September&#160;30, 2024; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">586,800 shares of Common Stock issuable upon the exercise of stock options outstanding as of September&#160;30, 2024, at a weighted-average exercise price of $19.66 per share under our Amended and Restated 2016 Incentive Award Plan, or the 2016 Incentive Award Plan, of which 12,386 options were vested as of September&#160;30, 2024; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">256,666 shares of Common Stock issuable upon the exercise of stock options outstanding as of September&#160;30, 2024, at a weighted-average exercise price of $20.10 per share under our Amended and Restated 2018 Employment Inducement Incentive Award Plan, or the Inducement Plan, of which no options were vested as of September&#160;30, 2024; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">1,128,723 shares of Common Stock issuable upon the exercise of stock options outstanding as of September&#160;30, 2024, at a weighted-average exercise price of $2.72 per share under the Cartesian Therapeutics, Inc. 2016 Stock Incentive Plan, or the 2016 Stock Incentive Plan, of which 964,490 options were vested as of September&#160;30, 2024; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">334,692 shares of Common Stock issuable upon the vesting of restricted stock units outstanding as of September&#160;30, 2024, at a weighted-average grant price of $19.88 under the 2016 Incentive Award Plan, of which no restricted stock units were vested as of September&#160;30, 2024; </div></td></tr></table></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 10-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20039376x3_s3_107-summary_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">113,519 shares of Common Stock issuable upon the vesting of restricted stock units outstanding as of September&#160;30, 2024, at a weighted-average grant price of $19.80 under the 2016 Stock Incentive Plan, of which no restricted stock units were vested as of September&#160;30, 2024; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">974,954 shares of Common Stock issuable upon the exercise of warrants outstanding as of September&#160;30, 2024, at a weighted average exercise price of $46.04 per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">3,511,101 shares of Common Stock reserved for issuance as of September&#160;30, 2024 under the 2016&#160;Incentive Award Plan; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">27,270 shares of Common Stock reserved for issuance as of September&#160;30, 2024 under the 2016 Stock Incentive Plan; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">253,377 shares of Common Stock reserved for issuance as of September&#160;30, 2024 under the Inducement Plan; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">45,795 shares of Common Stock reserved for issuance as of September&#160;30, 2024 pursuant to our 2016&#160;Employee Stock Purchase Plan. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For additional information concerning the offering, see the section titled &#8220;<font style="font-style: italic;">Plan of Distribution</font>.&#8221; </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 11-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_108-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRSF"><!--Anchor--></a>RISK FACTORS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in securities issued by us involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks described under the heading &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; in any of our filings with the SEC that are incorporated by reference herein. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 12-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_109-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUOP"><!--Anchor--></a>USE OF PROCEEDS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus, including all registration and filing fees, listing fees of the Nasdaq Stock Market LLC and fees and expenses of our counsel and our independent registered public accounting firm. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 13-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_110-desc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOC"><!--Anchor--></a>DESCRIPTION OF CAPITAL STOCK </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our restated certificate of incorporation, as amended, or the Charter, our amended and restated by-laws, or the Bylaws, and the applicable provisions of the Delaware General Corporation Law, or the DGCL. Each of our Charter and Bylaws is filed as an exhibit to the registration statement of which this prospectus forms a part. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">General </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of the date of this prospectus, our authorized capital stock consists of 360,000,000 shares, comprised of 350,000,000 shares of Common Stock and 10,000,000 shares of preferred stock, $0.0001 par value per share. As of September&#160;30, 2024 there were 23,896,525 shares of our Common Stock outstanding and 604,268.592 shares of preferred stock outstanding, of which (i) 166,341.592 were designated as Series&#160;A Non-Voting Convertible Preferred Stock, $0.0001 par value per share, or the Series&#160;A Preferred Stock, and are convertible into 5,544,719&#160;shares of Common Stock and (ii) 437,927 were designated as Series&#160;B Non-Voting Convertible Preferred Stock, $0.0001 par value per share, or the Series&#160;B Preferred Stock, and are convertible into 437,927&#160;shares of Common Stock. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Common Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our Common Stock is listed on the Nasdaq Global Market under the symbol &#8220;RNAC.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Voting Rights<font style="font-style: normal;">. Holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our Charter and Bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least a majority of the voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our Charter. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Rights upon Liquidation<font style="font-style: normal;">. In the event of our liquidation or dissolution, the holders of Common Stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Dividend Rights<font style="font-style: normal;">. Holders of Common Stock are entitled to receive proportionately any dividends as may be declared by our board of directors, or the Board of Directors, subject to any preferential dividend rights of outstanding preferred stock. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other Rights<font style="font-style: normal;">. Holders of Common Stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Preferred Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the Charter, the Board of Directors has the authority, without stockholder approval, subject to limitations prescribed by law, to provide for the issuance of up to 10,000,000 shares of preferred stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware, to establish from time to time the number of shares to be included in each such series, and to fix the voting rights, if any, designations, powers, preferences and relative, participating, optional, special and other rights of the shares of each series and any qualifications, limitations or restrictions thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will fix the voting rights, designations, preferences and rights of the preferred stock of each series, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to such series. We will file an exhibit to the registration statement of which any prospectus relating to offers and sales of </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 14-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_110-desc_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">any such preferred stock forms a part, or will incorporate by reference from reports that we file with the SEC,&#160;the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the title and stated value; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number of shares offered; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the liquidation preference per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the purchase price per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation for dividends; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether dividends are cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our right, if any, to defer payment of dividends and the maximum length of such deferral period; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the procedures for auction and remarketing, if any; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the provisions for a sinking fund, if any; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the provision for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any listing of the preferred stock on any securities exchange or market; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms and conditions, if applicable, upon which the preferred stock will be convertible into Common Stock, including the conversion price (or manner of calculation) and conversion period; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">voting rights, if any, of the preferred stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">preemptive rights, if any; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on transfer, sale or other assignment, if any; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether interests in the preferred stock will be represented by depositary shares; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the liquidation, dissolution or winding up of our affairs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other specific terms, preferences, rights, limitations or restrictions of the preferred stock. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our Board of Directors could authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of discouraging a takeover or other transaction that might involve a premium price for holders of the shares or which holders might believe to be in their best interests. The issuance of preferred stock could adversely affect the voting power, conversion or other rights of holders of Common Stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The laws of the State of Delaware provide that the holders of preferred stock will have the right to vote separately as a class on any proposal involving fundamental changes to the rights of holders of such preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The transfer agent and registrar for any series of preferred stock will be set forth in the applicable prospectus supplement. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 15-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_110-desc_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Series&#160;A Preferred Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Conversion<font style="font-style: normal;">. The outstanding shares of Series&#160;A Preferred Stock may convert into shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series&#160;A Preferred Stock (except for any holder of Series&#160;A Preferred Stock who beneficially owned greater than 19.9% of our Common Stock immediately prior to the Merger) is prohibited from converting shares of Series&#160;A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 0% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion, or the Series&#160;A Beneficial Ownership Limitation. Each outstanding share of Series&#160;A Preferred Stock is convertible, at any time and from time to time, at the option of the holder thereof, into 33.333 shares of Common Stock, subject to the Series&#160;A Beneficial Ownership Limitation and only to the extent the same shall have ceased to apply. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Voting Rights<font style="font-style: normal;">. Except as otherwise required by law (e.g., voting on a change to the authorized shares of Series&#160;A Preferred Stock or the rights of such shares as required by the DGCL) and the Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;A Preferred Stock, or the Series&#160;A Certificate of Designation, the Series&#160;A Preferred Stock does not have voting rights. However, as long as any shares of Series&#160;A Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series&#160;A Preferred Stock, (b) alter or amend the Series&#160;A Certificate of Designation, (c)&#160;amend the Charter or other organizational documents in any matter that adversely affects any rights of the holders of Series&#160;A Preferred Stock, (d) issue further shares of Series&#160;A Preferred Stock (other than in connection with the exercise of assumed Cartesian options to purchase shares of Series&#160;A Preferred Stock), (e) at any time while at least 30% of the originally issued Series&#160;A Preferred Stock remains issued and outstanding, consummate either (A) a Fundamental Transaction (as defined in the Series&#160;A Certificate of Designation) or (B) any merger or consolidation of the Company or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction, (f) amend or fail to comply with, in any manner that would be reasonably likely to prevent, impede or materially delay the conversion (or the stockholder approval thereof), or terminate, any of the support agreements entered into in connection with the Merger, or the Support Agreements, or agree to any transfer, sale or disposition of such shares subject to the Support Agreements (except for such transfers, sales or dispositions with respect to which the approval of the Company is not required pursuant to the applicable Support Agreement) or (g) enter into any agreement with respect to any of the foregoing. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Dividends<font style="font-style: normal;">. Holders of Series&#160;A Preferred Stock are entitled to receive non-cumulative dividends on shares of Series&#160;A Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the Common Stock. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Liquidation and Dissolution<font style="font-style: normal;">. The Series&#160;A Preferred Stock ranks on parity with Common Stock and Series&#160;B&#160;Preferred Stock upon any liquidation, dissolution or winding-up of the Company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Preemptive Rights<font style="font-style: normal;">. The Series&#160;A Preferred Stock does not have preemptive rights. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Transferability<font style="font-style: normal;">. The Series&#160;A Certificate of Designation does not contain any restrictions upon the transfer of the Series&#160;A Preferred Stock. </font></div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Series&#160;B Preferred Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Conversion<font style="font-style: normal;">. The outstanding shares of Series&#160;B Preferred Stock may convert into shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series&#160;B Preferred Stock (except for any holder of Series&#160;B Preferred Stock who beneficially owned greater than 19.9% of our Common Stock immediately prior to the Private Placement) is prohibited from converting shares of Series&#160;B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 0% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion, or the Series&#160;B Beneficial Ownership Limitation. Each outstanding share of Series&#160;B Preferred Stock is convertible, at any time and from time to time, at the option of the holder thereof, into one share of Common Stock, subject to the Series&#160;B Beneficial Ownership Limitation and only to the extent the same shall have ceased to apply. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 16-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_110-desc_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Voting Rights<font style="font-style: normal;">. Except as otherwise required by law (e.g., voting on a change to the authorized shares of Series&#160;B Preferred Stock or the rights of such shares as required by the DGCL) and the Certificate of Designation of Preferences, Rights, and Limitations of the Series&#160;B Preferred Stock, or the Series&#160;B Certificate of Designation, the Series&#160;B Preferred Stock does not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b) alter or amend the Series&#160;B Certificate of Designation, or (c)&#160;amend the Charter or other organizational documents in any matter that adversely affects any rights of the holders of Series&#160;B Preferred Stock. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Dividends<font style="font-style: normal;">. Holders of Series&#160;B Preferred Stock are entitled to receive non-cumulative dividends on shares of Series&#160;B Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the Common Stock. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Liquidation and Dissolution<font style="font-style: normal;">. The Series&#160;B Preferred Stock ranks on parity with Common Stock and Series&#160;A Preferred Stock upon any liquidation, dissolution or winding-up of the Company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Preemptive Rights<font style="font-style: normal;">. The Series&#160;B Preferred Stock does not have preemptive rights. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Transferability<font style="font-style: normal;">. The Series&#160;B Certificate of Designation does not contain any restrictions upon the transfer of the Series&#160;B Preferred Stock. </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Registration Rights </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain holders of our Common Stock or their transferees are entitled to the following rights with respect to the registration of such shares for public resale under the Securities Act. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These registration rights are granted pursuant to (i) a registration rights agreement, or the RRA, we entered into in June&#160;2024 in connection with a private placement of our Common Stock and Series&#160;B Preferred Stock, (ii) a registration rights agreement, or the 2023 RRA, we entered into in November&#160;2023 in connection with a private placement of our Common Stock and Series&#160;A Preferred Stock, or the 2023 Private Placement, and the Merger, and (iii) a registration rights agreement, or the 2020 RRA, we entered into in connection with the private placement of our Common Stock, which closed on July&#160;31, 2020. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 20pt; text-align: left;">RRA </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On July&#160;2, 2024, we entered into the RRA with the purchasers party thereto. Pursuant to the RRA, we were obligated to prepare and file a resale registration statement with the SEC within 30 days of July&#160;3, 2024 and to use our reasonable best efforts to cause such registration statement to be declared effective by the SEC within 90&#160;calendar days of July&#160;3, 2024 (or within 120 calendar days of July&#160;3, 2024 if the SEC reviews the registration statement). We also undertook to register the Resale Shares on a registration statement on Form&#160;S-3 promptly after such form is available to us. The registration statement of which this prospectus forms a part is intended to continue the satisfaction of these obligations, which were initially satisfied by our filing of a prior registration statement on Form&#160;S-1 relating to the resale of such securities, which we intend to terminate upon the effectiveness of this registration statement. Once this registration statement is declared effective, the Resale Shares to which the registration statement relates will no longer constitute restricted securities and may be sold freely in the public markets, subject to lapse on any related contractual restrictions related thereto of any holder party thereto, and subject to any restrictions that may be applicable to any control securities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We also agreed, among other things, to indemnify the purchasers party thereto and each of their respective officers, directors, agents, partners, members, managers, stockholders, affiliates, investment advisers and employees, each person who controls any such purchaser party and the officers, directors, partners, members, managers, stockholders, agents, investment advisers and employees of each such controlling person from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the RRA. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Securities of a holder cease to be registrable securities under the RRA upon the earlier to occur of the following: (A) a sale pursuant to a registration statement or Rule&#160;144 under the Securities Act; and (B) the time such shares become eligible for resale by such holder under Rule&#160;144 without the requirement for the Company to be in compliance with the current public information required by Rule&#160;144(c) and Rule&#160;144(i)(2) and without </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 17-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_110-desc_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">volume or manner-of-sale restrictions, pursuant to a written opinion letter of counsel for the Company to such effect, addressed, delivered and reasonably acceptable to the Company&#8217;s transfer agent. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">2023 RRA </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the Merger and the 2023 Private Placement, we entered into the 2023 RRA, pursuant to which we agreed to prepare and file a resale registration statement with the SEC within 90 calendar days following November&#160;15, 2023, with respect to the shares of Common Stock underlying the Series&#160;A Preferred Stock issued in the 2023 Private Placement and the Common Stock and Series&#160;A Preferred Stock issued to the signatories to the 2023 RRA in the Merger. We also agreed to use our commercially reasonable efforts to cause such registration statement to be declared effective by the SEC by March&#160;29, 2024 (or by May&#160;13, 2024 if the SEC reviews the registration statement). The parties to the 2023 RRA previously waived these registration requirements during the period in which we were not eligible to use Form S-3 to register resales of the registrable securities under the 2023 RRA, and one signatory to the 2023 RRA has irrevocably waived such registration requirements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We also agreed to, among other things, indemnify the holders of Common Stock and Series&#160;A Preferred Stock signatory thereto, their officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents under such registration statement from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the 2023 RRA. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Securities of a holder cease to be registrable securities under the 2023 RRA upon the earlier to occur of the following: (A) a sale pursuant to a registration statement or Rule&#160;144 under the Securities Act; and (B) the time such shares become eligible for resale by such holder under Rule&#160;144 without the requirement for the Company to be in compliance with the current public information required thereunder and without volume or manner-of-sale restrictions, pursuant to a written opinion letter of counsel for the Company to such effect, addressed, delivered and reasonably acceptable to the Company&#8217;s transfer agent. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">2020 RRA </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of registrable securities under the 2020 RRA have registration rights until the earlier of (i) such time as there are no longer any registrable securities held by the purchaser, its affiliates or permitted transferees and (ii) such time as all of the securities can otherwise be sold without regard to the volume or manner-of-sale restrictions pursuant to Rule&#160;144. The registration of shares of Common Stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Piggyback Registration Rights<font style="font-style: normal;">. Any time we propose to register any shares of our Common Stock under the Securities Act, subject to certain exceptions, the holders of registrable securities are entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Demand Registration Rights<font style="font-style: normal;">. If the holders of registrable securities request in writing that we effect a registration with respect to all of the registrable securities, we will be required to effect such registration. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Expenses<font style="font-style: normal;">. Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling security holders and blue sky fees and expenses. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Termination of Registration Rights<font style="font-style: normal;">. The registration rights terminate upon the earlier of (i) such time as there are no longer any registrable securities held by the purchaser, its affiliates or permitted transferees and (ii)&#160;such time as all of the securities can otherwise be sold without regard to the volume or manner-of-sale restrictions pursuant to Rule&#160;144. </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Anti-Takeover Effects of Delaware Law and Our Charter and Bylaws </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Some provisions of the DGCL, our Charter and our Bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 18-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_110-desc_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interest, including transactions which provide for payment of a premium over the market price for our shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first&#160;negotiate with our Board of Directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Undesignated Preferred Stock<font style="font-style: normal;">. The ability of our Board of Directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our Board of Directors could impede the success of any attempt to effect a change in control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Stockholder Meetings<font style="font-style: normal;">. Our Bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our Board of Directors. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Requirements for Advance Notification of Stockholder Nominations and Proposals<font style="font-style: normal;">. Our Bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the Board of Directors or a committee of the Board of Directors. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Elimination of Stockholder Action by Written Consent<font style="font-style: normal;">. Our Charter eliminates the right of stockholders to act by written consent without a meeting. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Staggered Board<font style="font-style: normal;">. Our Board of Directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Removal of Directors<font style="font-style: normal;">. Our Charter provides that no member of our Board of Directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Stockholders Not Entitled to Cumulative Voting<font style="font-style: normal;">. Our Charter does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our Common Stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Delaware Anti-Takeover Statute<font style="font-style: normal;">. We are subject to Section&#160;203 of the DGCL, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this law may have an anti-takeover effect with respect to transactions not approved in advance by the Board of Directors. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Choice of Forum<font style="font-style: normal;">. Our Charter provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 19-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_110-desc_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&#160;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our Charter or Bylaws; or (4) any action asserting a claim governed by the internal affairs doctrine. Our Charter also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our Charter is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. Investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section&#160;22 of the Securities Act generally creates concurrent jurisdiction for state and federal courts over suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Section&#160;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Amendment of Charter<font style="font-style: normal;">. The amendment of any of the above provisions in our Charter, except for the provision making it possible for our Board of Directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote thereon. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The provisions of the DGCL, our Charter and our Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our Board of Directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interest. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The transfer agent and registrar for our Common Stock, Series&#160;A Preferred Stock, and Series&#160;B Preferred Stock is Equiniti Trust Company, LLC. The transfer agent&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219, and its telephone number is (800) 937-5449. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Exchange Listing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our Common Stock is listed on the Nasdaq Global Market under the symbol &#8220;RNAC.&#8221; We have not applied to list the Series&#160;A Preferred Stock or the Series&#160;B Preferred Stock on any national securities exchange. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 20-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_111-stock_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSTO"><!--Anchor--></a>SELLING STOCKHOLDERS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus covers the resale or other disposition from time to time by the Selling Stockholders identified in the table below of up to an aggregate of 6,251,150 shares of our Common Stock. The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares set forth below pursuant to this prospectus and any accompanying prospectus supplement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On July&#160;2, 2024, we entered into a securities purchase agreement, or the Securities Purchase Agreement, for a private placement with certain institutional and accredited investors, pursuant to which we sold an aggregate of 3,563,247 shares of our Common Stock and 2,937,903 shares of our Series&#160;B Preferred Stock for an aggregate purchase price of approximately $130&#160;million. On September&#160;25, 2024, 2,499,976 shares of Series&#160;B Preferred Stock issued in the Private Placement converted into 2,499,976 shares of Common Stock. Each of the remaining 437,927 shares of Series&#160;B Preferred Stock is convertible into one share of Common Stock, subject to certain beneficial ownership limitations, pursuant to the Series&#160;B Certificate of Designation. This prospectus covers the resale or other disposition by the Selling Stockholders or their pledgees, donees, transferees or other successors-in-interest that receive their shares after the date of this prospectus of up to the total number of shares of Common Stock and shares of Common Stock issued or issuable upon the conversion of the Series&#160;B Preferred Stock sold to the Selling Stockholders pursuant to the Securities Purchase Agreement. Throughout this prospectus, when we refer to the &#8220;Selling Stockholders,&#8221; we are referring to the purchasers under the Securities Purchase Agreement listed in the table below. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are registering the Resale Shares to permit the Selling Stockholders and their pledgees, donees, transferees or other successors-in interest that receive their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under &#8220;<font style="font-style: italic;">Plan of Distribution</font>&#8221; herein. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as otherwise disclosed herein, the Selling Stockholders do not have, and within the past three years have not had, any position, office or other material relationship with us. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth the names of the Selling Stockholders, the number of shares of our Common Stock owned by the Selling Stockholders (assuming the conversion of all outstanding shares of Series&#160;B Preferred Stock held by such Selling Stockholder), the number of shares of our Common Stock that may be offered under this prospectus (which reflects the assumed conversion of all outstanding shares of Series&#160;B Preferred Stock) and the number of shares of our Common Stock that will be owned after this offering by the Selling Stockholders assuming all of the Resale Shares registered for resale hereby are sold, in each case as of November&#160;22, 2024. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholders may sell some, all or none of their Resale Shares. We do not know how long the Selling Stockholders will hold the Resale Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other disposition of any of the Resale Shares. The Resale Shares covered hereby may be offered from time to time by the Selling Stockholders, provided that Resale Shares issued upon conversion of Series&#160;B Preferred Stock may only be offered after such shares of Series&#160;B Preferred Stock are converted to Common Stock pursuant to the terms of the Series&#160;B Certificate of Designation, subject to certain beneficial ownership limitations. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">18<br></div></div></div>
<!--End Page 21-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_111-stock_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The information set forth below is based upon information obtained from the Selling Stockholders and upon information in our possession regarding the issuance of the Series&#160;B Preferred Stock and Private Placement Common Shares in connection with the Private Placement, and the issuance of Private Placement Conversion Shares upon conversion of the Series&#160;B Preferred Stock. The percentages of Common Stock owned after the offering by each Selling Stockholder below are based on 25,725,306 shares of Common Stock outstanding as of November&#160;22, 2024, and, for each Selling Stockholder, assumes the conversion of only the Series&#160;B Preferred Stock owned by such Selling Stockholder but not the Series&#160;B Preferred Stock owned by any other Selling Stockholder. The numbers of shares of Common Stock beneficially owned before and after the offering presented in the table below do not give effect to the Series&#160;B Beneficial Ownership Limitation, but do give effect to the Series&#160;A Beneficial Ownership Limitation. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40.87pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 88.99pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Selling Stockholders<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td style="width: 5.69pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Before <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offering<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td style="width: 5.69pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock that <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">May <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Be Offered <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pursuant to <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Prospectus</div></td><td style="width: 5.69pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 88.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned After <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offering<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup> </div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number</div></td><td style="width: 5.69pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(%) </div></td></tr><tr><td style="width: 264pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities affiliated with Timothy A. Springer, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 1.14pt;"></font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9,481,816</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;">2,359,500</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">7,122,316</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;">27.5% </div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Schooner Century Fund LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 3.34pt;"></font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,608,709</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">737,500</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">871,209</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 5pt;">3.3% </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fidelity Growth Company Commingled Pool<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 3.34pt;"></font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">461,147</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">461,147</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fidelity Select Portfolios: Biotechnology Portfolio<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 2.24pt;"></font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">884,159</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">375,000</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">509,159</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 5pt;">2.0% </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Citadel CEMF Investments Ltd.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup><font style="padding-left: 1.95pt;"></font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">375,000</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">375,000</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fidelity Select Portfolios: Select Health Care Portfolio<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup><font style="padding-left: 4.5pt;"></font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">368,992</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">368,992</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup><font style="padding-left: 2.2pt;"></font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">341,346</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">341,346</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Invus Public Equities, L.P.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup><font style="padding-left: 0.41pt;"></font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">616,210</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">250,000</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">366,210</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 5pt;">1.4% </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Fidelity Advisor Series&#160;VII: Fidelity Advisor Health Care Fund<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(11)</sup><font style="padding-left: 3.72pt;"></font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">230,254</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">230,254</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">HBM Healthcare Investments (Cayman) Ltd.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(12)</sup><font style="padding-left: 4.91pt;"></font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">200,000</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">200,000</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Fidelity Advisor Series&#160;VII: Fidelity Advisor Biotechnology Fund<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(13)</sup><font style="padding-left: 3.45pt;"></font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">167,950</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">167,950</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(14)</sup><font style="padding-left: 3.45pt;"></font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">108,576</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">108,576</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Armistice Capital, LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(15)</sup><font style="padding-left: 2.64pt;"></font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">100,000</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 7.5pt;">100,000</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Fidelity Mt. Vernon Street Trust: Fidelity Series&#160;Growth Company Fund<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(16)</sup><font style="padding-left: 1.23pt;"></font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">88,931</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 12.5pt;">88,931</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Variable Insurance Products Fund IV: VIP Health Care Portfolio<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(17)</sup><font style="padding-left: 3.45pt;"></font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">56,954</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 12.5pt;">56,954</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">683 Capital Partners, LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(18)</sup><font style="padding-left: 3.2pt;"></font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">30,000</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.87pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 12.5pt;">30,000</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.61pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.87pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.61pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 9.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To our knowledge, unless otherwise indicated, all persons named in the table above have sole voting and investment power with respect to their shares of Common Stock. Unless otherwise indicated, the address of each beneficial owner listed below is 7495&#160;New&#160;Horizon Way, Frederick, Maryland 21703. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">&#8220;Beneficial ownership&#8221; is a term broadly defined by the SEC in Rule&#160;13d-3 under the Exchange Act, and includes more than the typical form of stock ownership, that is, stock held in the person&#8217;s name. The term also includes what is referred to as &#8220;indirect ownership,&#8221; meaning ownership of shares as to which a person has or shares investment power. Notwithstanding the foregoing, the beneficial ownership amounts assume the sale of all Common Stock that may be offered pursuant to this prospectus without taking into account certain limitations, including the Series&#160;B Beneficial Ownership Limitation, of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of (i) 8,449,773 shares of Common Stock held directly by Timothy A. Springer, Ph.D., a member of our Board of Directors, (ii) 113,587 shares of Common Stock issuable upon exercise of underlying warrants exercisable within 60 days of November&#160;22, 2024 held directly by Timothy A. Springer, Ph.D., (iii) 2,533 shares of Common Stock issuable upon exercise of outstanding options within 60 days of November&#160;22, 2024 and held directly by Timothy A. Springer, Ph.D., (iv)&#160;1,977&#160;shares of Common Stock underlying restricted stock units vesting within 60 days of November&#160;22, 2024, (v) 529,798 shares of Common Stock held by TAS Partners LLC, or TAS, directly, (vi) 33,408 shares of Common Stock issuable upon exercise of underlying warrants exercisable within 60 days of November&#160;22, 2024 held by TAS directly, (vii) 330,695 shares of Common Stock held by Dr.&#160;Chafen Lu, Dr.&#160;Springer&#8217;s wife, and (viii) 20,045 shares of Common Stock issuable upon exercise of underlying warrants exercisable within 60&#160;days of November&#160;22, 2024 held by Dr.&#160;Chafen Lu. Dr.&#160;Springer is the sole managing member of TAS. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">19<br></div></div></div>
<!--End Page 22-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_111-stock_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5.25pt; margin-left: 20pt; text-align: left;">Dr.&#160;Springer exercises sole voting and dispositive power over the shares held by him directly and the shares held by TAS. Dr.&#160;Springer disclaims beneficial ownership of the shares held by TAS. Dr.&#160;Lu exercises sole voting and dispositive power over the shares held by her directly. The principal business address of each of Dr.&#160;Springer, TAS, and Dr.&#160;Lu is 36 Woodman Road, Newton, MA, 02467. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, the Resale Shares that are registered for resale hereby consists of 299,573 shares of Common Stock and 437,927 shares of Common Stock underlying Series&#160;B Preferred Stock held directly by Schooner Century Fund LLC. Schooner&#160;Century Fund LLC also holds 871,209 shares of Common Stock that are not registered for resale hereby. Additionally, Schooner Century Fund LLC holds 2,146,271 shares of Common Stock underlying outstanding shares of Series&#160;A Preferred Stock that are not registered for resale hereby and are not reflected in the &#8220;Common Stock Beneficially Owned After Offering&#8221; columns in the table above. Schooner Capital LLC is the Sole Manager of Schooner Century Fund LLC. Schooner Capital LLC is managed by Stephen D. Maiocco, Edward D. Henderson, and Peter K. Binas, serving as its Managing Partners. These Managing Partners, along with Vincent J. Ryan as majority member of the Sole Manager share the sole voting discretion and dispositive power with respect to all shares of Cartesian Therapeutics, Inc. held by Schooner Century Fund LLC. The ability of the shares of Series&#160;A Preferred Stock or Series&#160;B Preferred Stock held by Schooner Century Fund LLC to convert into shares of Common Stock are subject to beneficial ownership limitations, such that Schooner Century Fund LLC may not convert shares of Series&#160;A Preferred Stock or Series&#160;B Preferred Stock into Common Stock to the extent that doing so would result in such holder, together with its affiliates, beneficially owning greater than 4.9% of the Company's outstanding Common Stock after giving effect to any such conversion. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 461,147 shares of Common Stock held by Fidelity Growth Company Commingled Pool. This fund is managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series&#160;B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series&#160;B shareholders have entered into a shareholders&#8217; voting agreement under which all Series&#160;B&#160;voting common shares will be voted in accordance with the majority vote of Series&#160;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of this fund is 245 Summer Street, Boston, MA 02210. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 375,000 shares of Common Stock held by Fidelity Select Portfolios: Biotechnology Portfolio. Additionally, Fidelity Select Portfolios: Biotechnology Portfolio holds 509,159 shares of Common Stock that are not registered for resale hereby. This fund is managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series&#160;B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series&#160;B shareholders have entered into a shareholders&#8217; voting agreement under which all Series&#160;B voting common shares will be voted in accordance with the majority vote of Series&#160;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of this fund is 245 Summer Street, Boston, MA 02210. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 375,000 shares of Common Stock held directly by Citadel CEMF Investments Ltd. Citadel Advisors LLC is the portfolio manager of Citadel CEMF Investments Ltd. Citadel Advisors Holdings LP, or CAH, is the sole member of Citadel Advisors LLC. Citadel GP LLC, or CGP, is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr.&#160;Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or direct the disposition over, these securities. The address of Citadel CEMF Investments Ltd. is c/o&#160;Citadel Enterprise Americas LLC, Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL 33131. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 368,992 shares of Common Stock held by Fidelity Select Portfolios: Select Health Care Portfolio. This fund is managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series&#160;B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series&#160;B shareholders have entered into a shareholders&#8217; voting agreement under which all Series&#160;B voting common shares will be voted in accordance with the majority vote of Series&#160;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of this fund is 245 Summer Street, Boston, MA 02210. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 341,346 shares of Common Stock held by Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund. This fund is managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series&#160;B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series&#160;B shareholders have entered into a shareholders&#8217; voting agreement under which all Series&#160;B voting common shares will be voted in accordance with the majority vote of Series&#160;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR&#160;LLC. The address of this fund is 245 Summer Street, Boston, MA 02210. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 250,000 shares of Common Stock held directly by Invus Public Equities, L.P., or IPE. Additionally, IPE holds 322,237 shares of Common Stock and 43,973 shares of Common Stock underlying warrants that are exercisable within 60 days of the date hereof that are not registered for resale hereby. Invus Public Equities Advisors, LLC, or IPEA, controls IPE, as its general partner and accordingly, may be deemed to beneficially own the shares held by IPE. Invus Global Management, LLC, or IGM, controls IPEA, as its managing member and accordingly, may be deemed to beneficially own the shares that IPEA may be deemed to beneficially own. Siren, L.L.C., or Siren, controls IGM, as its managing member and accordingly, may be deemed to beneficially own the shares that IGM may be deemed to beneficially own. Mr.&#160;Raymond Debbane, as the managing member of Siren, controls Siren and accordingly, may be deemed to beneficially own the shares that Siren may be deemed to beneficially own. The address of Invus Public Equities, L.P. is 750 Lexington Ave, 30th Floor, New York, NY 10022. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(11)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 230,254 shares of Common Stock held by Fidelity Advisor Series&#160;VII: Fidelity Advisor Health Care Fund. This fund is managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">20<br></div></div></div>
<!--End Page 23-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_111-stock_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5.25pt; margin-left: 20pt; text-align: left;">predominant owners, directly or through trusts, of Series&#160;B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series&#160;B shareholders have entered into a shareholders&#8217; voting agreement under which all Series&#160;B voting common shares will be voted in accordance with the majority vote of Series&#160;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR&#160;LLC. The address of this fund is 245 Summer Street, Boston, MA 02210. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(12)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 200,000 shares of Common Stock held directly by HBM Healthcare Investments (Cayman) Ltd. Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd., or the HBM Board. The HBM Board consists of Jean-Marc Lesieur, Richard H. Coles, Sophia Harris, Dr.&#160;Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares.<font style="font-style: italic;"> </font>The address of HBM Healthcare Investments (Cayman) Ltd. is Governor&#8217;s Square, 23 Lime Tree Bay Ave., PO Box 30852, Grand Cayman, KY1-1204, Cayman Islands. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(13)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 167,950 shares of Common Stock held by Fidelity Advisor Series&#160;VII: Fidelity Advisor Biotechnology Fund. This fund is managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series&#160;B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series&#160;B shareholders have entered into a shareholders&#8217; voting agreement under which all Series&#160;B voting common shares will be voted in accordance with the majority vote of Series&#160;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR&#160;LLC. The address of this fund is 245 Summer Street, Boston, MA 02210. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(14)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 108,576 shares of Common Stock held by Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund. This fund is managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series&#160;B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series&#160;B shareholders have entered into a shareholders&#8217; voting agreement under which all Series&#160;B voting common shares will be voted in accordance with the majority vote of Series&#160;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR&#160;LLC. The address of this fund is 245 Summer Street, Boston, MA 02210. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(15)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 100,000 shares of Common Stock. The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, or the Master Fund, and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC, or Armistice Capital, as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(16)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 88,931 shares of Common Stock held by Fidelity Mt. Vernon Street Trust: Fidelity Series&#160;Growth Company Fund. This fund is managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series&#160;B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series&#160;B shareholders have entered into a shareholders&#8217; voting agreement under which all Series&#160;B voting common shares will be voted in accordance with the majority vote of Series&#160;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR&#160;LLC. The address of this fund is 245 Summer Street, Boston, MA 02210. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(17)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 56,954 shares of Common Stock held by Variable Insurance Products Fund&#160;IV:&#160;VIP&#160;Health Care Portfolio. This fund is managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series&#160;B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series&#160;B shareholders have entered into a shareholders&#8217; voting agreement under which all Series&#160;B voting common shares will be voted in accordance with the majority vote of Series&#160;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of this fund is 245 Summer Street, Boston, MA 02210. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(18)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information known to us, and consists of 30,000 shares of Common Stock. Ari Zweiman has voting and investment power with respect to these securities and therefore may be deemed to be the beneficial owner thereof. The address of 683 Capital Partners, LP is 1700 Broadway, Suite 4200, New York, NY 10019. </div></td></tr></table><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Relationship with the Selling Stockholders </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the Securities Purchase Agreement, in connection with the Private Placement, we entered into the RRA on July&#160;2, 2024 with the Selling Stockholders. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">21<br></div></div></div>
<!--End Page 24-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_111-stock_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><u>Private Placement</u> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Dr.&#160;Timothy A. Springer, TAS, and Dr.&#160;Springer&#8217;s spouse, Dr.&#160;Chafen Lu, purchased shares of our Series&#160;B Preferred Stock in the Private Placement. The following table sets forth the number of shares of Series&#160;B Preferred Stock purchased in the Private Placement by such parties: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 288pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 99.06pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 54.66pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 99.06pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares of Series&#160;B Preferred <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock Purchased</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total Aggregate <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Purchase Price </div></td></tr><tr><td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Timothy A. Springer, Ph.D.<font style="padding-left: 2.93pt;"></font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 99.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.53pt; text-align: left;">1,636,832</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.66pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.33pt; text-align: left;">$32,736,640 </div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">TAS Partners LLC (affiliate of Timothy A. Springer, Ph.D.)<font style="padding-left: 0.82pt;"></font></div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 99.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.53pt; text-align: left;"><font style="padding-left: 7.5pt;">721,361</font></div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.33pt; text-align: left;">$14,427,220 </div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chafen Lu, Ph.D.<font style="padding-left: 3.58pt;"></font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 99.06pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.53pt; text-align: left;"><font style="padding-left: 17.5pt;">1,307</font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.66pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.33pt; text-align: left;">$<font style="padding-left: 17.5pt;">26,140</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 288pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 99.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 54.66pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 16pt; margin-left: 0pt; text-align: left;"><u>2023 Private Placement</u> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the 2023 Private Placement, we entered into a securities purchase agreement pursuant to which we issued and sold an aggregate of 149,330.115 shares of Series&#160;A Preferred Stock, each of which was converted or is convertible into 33.333 shares of Common Stock, for an aggregate purchase price of approximately $60.25&#160;million. Timothy A. Springer, Ph.D., one of the Selling Stockholders and a member of our Board of Directors, participated in the 2023 Private Placement and was party to the 2023 RRA. TAS is affiliated with Dr.&#160;Springer and TAS also participated in the 2023 Private Placement and was party to the 2023 RRA. The following table sets forth the number of shares of Series&#160;A Preferred Stock purchased in 2023 Private Placement by such parties: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 300pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 98.63pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 54.66pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 300pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td style="width: 3.68pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.68pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 98.63pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares of Series&#160;A Preferred <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock Purchased</div></td><td style="width: 3.68pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.68pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total Aggregate <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Purchase Price </div></td></tr><tr><td style="width: 300pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Timothy A. Springer, Ph.D.<font style="padding-left: 4.93pt;"></font></div></td><td style="width: 3.68pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.68pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 98.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.31pt; text-align: left;">123,925.407</div></td><td style="width: 3.68pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.68pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.66pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.33pt; text-align: left;">$50,000,000 </div></td></tr><tr><td style="width: 300pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">TAS Partners LLC (affiliate of Timothy A. Springer, Ph.D.)<font style="padding-left: 2.82pt;"></font></div></td><td style="width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 98.63pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.31pt; text-align: left;"><font style="padding-left: 5pt;">24,785.081</font></div></td><td style="width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.66pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.33pt; text-align: left;">$10,000,000</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 300pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 98.63pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.68pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 54.66pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the 2023 Private Placement, Dr.&#160;Timothy A. Springer agreed to settle his purchases in three tranches of shares of Series&#160;A Preferred Stock, the first for a purchase price of $10.0&#160;million and each thereafter for a purchase price of approximately $20.0&#160;million, with the three tranches settling 30, 60, and 90 days, respectively, following the closing of the transaction. TAS agreed to settle its purchase for approximately $10.0&#160;million within 30 days following the closing of the transaction. The first, second and third tranches were settled on December&#160;13, 2023, January&#160;12, 2024 and February&#160;11, 2024, respectively, under which (i) 24,785.081 shares of Series&#160;A Preferred Stock were issued to each of TAS and Dr.&#160;Timothy A. Springer in the first tranche, (ii)&#160;49,570.163 shares of Series&#160;A Preferred Stock were issued to Dr.&#160;Timothy A. Springer in the second tranche, and (iii) 49,570.163 shares of Series&#160;A Preferred Stock were issued to Dr.&#160;Timothy A. Springer in the third&#160;tranche. </div><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18pt; margin-left: 0pt; text-align: left;"><u>Warrant Exercise</u> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;26, 2024, TAS exercised 65,681 warrants originally issued in 2019 (and amended in December&#160;2022), paid the per-share exercise price of $43.80 in cash for an aggregate exercise price of $2.9&#160;million, and received 65,681 shares of Common Stock and 1,970,443 CVRs. </div><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18pt; margin-left: 0pt; text-align: left;"><u>Registration Rights Agreement</u> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the terms of the RRA, we agreed to prepare and file with the SEC a registration statement that permits the resale or other disposition of the Selling Stockholders&#8217; shares of Common Stock issued and shares of Common Stock issuable upon conversion of the Series&#160;B Preferred Stock issued to such Selling Stockholders pursuant to the Securities Purchase Agreement and, subject to certain exceptions, use commercially reasonable efforts to keep the registration statement of which this prospectus forms a part effective under the Securities Act for so long as such securities registered for resale thereunder retain their character as Registrable Securities (as defined in the RRA). We also undertook to register the Resale Shares on a registration statement on Form&#160;S-3 promptly after such form is available to us. The registration statement of which this prospectus forms a part is intended to continue the satisfaction of these obligations, which were initially satisfied by our filing of a prior registration statement on Form&#160;S-1 relating to the resale of such securities, which we intend to terminate upon the effectiveness of this registration statement. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">22<br></div></div></div>
<!--End Page 25-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_111-stock_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have also agreed, among other things, to indemnify the Selling Stockholders and each of their respective officers, directors, agents, partners, members, managers, stockholders, affiliates, investment advisers and employees, each person who controls any such Selling Stockholder and the officers, directors, partners, members, managers, stockholders, agents, investment advisers and employees of each such controlling person from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the RRA. </div><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><u>April&#160;2022 Offering</u> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In April&#160;2022, we completed an SEC-registered securities offering pursuant to which we issued and sold an aggregate of 914,285 shares of our Common Stock and accompanying warrants to purchase 685,712 shares of our Common Stock, at a combined purchase price of $42.30, for aggregate net proceeds to us of approximately $36.9&#160;million. In this offering, TAS purchased 222,720 shares of Common Stock and warrants to purchase 167,040 shares of Common Stock for a total purchase price of approximately $9.4&#160;million. </div><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><u>Support Agreements</u> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the execution of the Merger Agreement, we and Old Cartesian entered into the Support Agreements with certain of our pre-Merger officers, directors and stockholders, including Dr.&#160;Springer and TAS. Pursuant to the Support Agreements, among other things, each of our pre-Merger stockholder parties thereto agreed to vote or cause to be voted all of the shares of Common Stock owned by such stockholder in favor of the proposals we submitted for stockholder approval at our March&#160;2024 special meeting of stockholders. </div><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><u>Indemnification Agreements</u> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have entered into indemnification agreements with each of our directors and executive officers, including Dr.&#160;Springer. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or an executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of such person&#8217;s services as a director or executive officer. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">23<br></div></div></div>
<!--End Page 26-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_112-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPOD"><!--Anchor--></a>PLAN OF DISTRIBUTION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are registering resales of Resale Shares to permit the sale, transfer or other disposition of the Resale Shares by the Selling Stockholders or their donees, pledgees, transferees or other successors-in-interest from time&#160;to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling Stockholders of the Resale Shares. We will, or will procure to, bear all fees and expenses incident to our obligation to register the Resale Shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time, and in the case of shares of Common Stock issuable upon the conversion of the Series&#160;B Preferred Stock, may only be offered after such shares are converted to shares of Common Stock pursuant to the terms of the Series&#160;B Certificate of Designation, directly or through one or more underwriters, broker-dealers or agents. If the Resale Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts (it being understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering) or commissions or agent&#8217;s commissions. The Resale Shares may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when selling Resale Shares: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exchange distribution in accordance with the rules of the applicable exchange; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">privately negotiated transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">broker-dealers may agree with the Selling Stockholders to sell a specified number of such Resale Shares at a stipulated price per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through the writing or settlement of options or other hedging transactions, whether such options are listed on an options exchange or otherwise; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a combination of any such methods of sale; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other method permitted pursuant to applicable law. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholders also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule&#160;144 under the Securities Act, as permitted by that rule, or Section&#160;4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect such transactions by selling Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers of the Resale Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule&#160;2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2121.01. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">24<br></div></div></div>
<!--End Page 27-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 28-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_112-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with sales of the Resale Shares or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Resale Shares in the course of hedging in positions they assume. The Selling Stockholders may also sell Resale Shares short and if such short sale takes place after the date that this Registration Statement is declared effective by the SEC, the Selling Stockholders may deliver Resale Shares covered by this prospectus to close out short positions and to return borrowed Resale Shares in connection with such short sales. The Selling Stockholders may also loan or pledge Resale Shares to broker-dealers that in turn may sell such Resale Shares, to the extent permitted by applicable law. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the Selling Stockholders have been advised that they may not use Resale Shares the resale of which has been registered on this registration statement to cover short sales of our Common Stock made prior to the date the registration statement, of which this prospectus forms a part, has been declared effective by the SEC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the Resale Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Resale Shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule&#160;424(b)(3) or other applicable provision of the Securities Act, amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The Selling Stockholders also may transfer and donate the Resale Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Stockholders and any broker-dealer or agents participating in the distribution of the Resale Shares may be deemed to be &#8220;underwriters&#8221; within the meaning of Section&#160;2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are &#8220;underwriters&#8221; within the meaning of Section&#160;2(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act including Rule&#160;172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and Rule&#160;10b-5 under the Exchange Act. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each Selling Stockholder has informed the Company that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Resale Shares. Upon the Company being notified in writing by a selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of Common Stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule&#160;424(b) under the Securities Act, disclosing (i) the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of Resale Shares involved, (iii) the price at which such the Resale Shares were sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out in this prospectus, and (vi) other facts material to the transaction. In no event shall any broker-dealer receive fees, commissions and markups, which, in the aggregate, would exceed eight percent (8.0%). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the securities laws of some U.S. states, the Resale Shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some U.S. states the Resale Shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There can be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the shelf registration statement of which this prospectus forms a part. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each Selling Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">25<br></div></div></div>
<!--End Page 28-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 29-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_112-plan_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Resale Shares by the Selling Stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Resale Shares to engage in market-making activities with respect to the Resale Shares. All of the foregoing may affect the marketability of the Resale Shares and the ability of any person or entity to engage in market-making activities with respect to the Resale Shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will pay all expenses of the registration of the Resale Shares pursuant to the registration rights agreement, including, without limitation, SEC filing fees and expenses of compliance with state securities or &#8220;blue sky&#8221; laws; provided, however, that each Selling Stockholder will pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. We will indemnify the Selling Stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the RRA, or the Selling Stockholders will be entitled to contribution. We may be indemnified by the Selling Stockholders against certain civil liabilities set forth in the RRA, including liabilities under the Securities Act, that may arise from any written information furnished to us by the Selling Stockholders specifically for use in this prospectus, in accordance with the related RRA, or we may be entitled to contribution. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">26<br></div></div></div>
<!--End Page 29-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 30-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_113-legal_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLMA"><!--Anchor--></a>LEGAL MATTERS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities will be passed upon for us by Covington &amp; Burling LLP, New York, New York. If legal matters are passed upon by counsel for the underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating to such offering. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">27<br></div></div></div>
<!--End Page 30-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 31-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_113-legal_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tEXP"><!--Anchor--></a>EXPERTS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2023 and the effectiveness of our internal control over financial reporting as of December&#160;31, 2023, as set forth in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP's reports, given on their authority as experts in accounting and auditing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The financial statements of Cartesian Therapeutics, Inc. as of and for the years ended December&#160;31, 2022 and 2021 appearing in the Current Report on Form&#160;8-K/A filed on January&#160;23, 2024 of Cartesian Therapeutics, Inc. (formerly known as Selecta Biosciences, Inc.) incorporated by reference in this Prospectus and in the Registration Statement have been so incorporated in reliance on the report of BDO USA, P.C., independent auditors, given on the authority of said firm as experts in auditing and accounting. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">28<br></div></div></div>
<!--End Page 31-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 32-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_300-part-2_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PART II <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">INFORMATION NOT REQUIRED IN PROSPECTUS </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-style: italic;">Other Expenses of Issuance and Distribution</font> </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is an estimate, other than with respect to the SEC registration fee, of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 401pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 52.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 401pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SEC registration fee<font style="padding-left: 0.76pt;"></font></div></td><td style="width: 7.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.5pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 20pt;">&#8203;19,993 </font></div></td></tr><tr><td style="width: 401pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Printing expenses<font style="padding-left: 1.86pt;"></font></div></td><td style="width: 7.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 25pt;">&#8203;4,000 </font></div></td></tr><tr><td style="width: 401pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legal fees and expenses<font style="padding-left: 4.11pt;"></font></div></td><td style="width: 7.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$&#8195;&#8195;75,000 </div></td></tr><tr><td style="width: 401pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting fees and expenses<font style="padding-left: 0.22pt;"></font></div></td><td style="width: 7.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 20pt;">&#8203;55,000 </font></div></td></tr><tr><td style="width: 401pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous<font style="padding-left: 0.74pt;"></font></div></td><td style="width: 7.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</font><font style="padding-left: 25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8203;</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,007 </font></div></td></tr><tr><td style="width: 401pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 3.09pt;"></font></div></td><td style="width: 7.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 15pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8203;</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">155,000</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 401pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 52.5pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-style: italic;">Indemnification of Directors and Officers</font><font style="font-weight: normal;"> </font></div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subsection (a) of Section&#160;145 of the General Corporation Law of the State of Delaware, or the DGCL, empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#8217;s conduct was unlawful. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subsection (b) of Section&#160;145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section&#160;145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section&#160;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&#160;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section&#160;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators. Section&#160;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&#160;145. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br></div></div></div>
<!--End Page 32-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 33-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_300-part-2_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section&#160;102(b)(7) of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section&#160;174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any underwriting agreement or distribution agreement that the registrant enters into with any underwriters or agents involved in the offering or sale of any securities registered hereby may require such underwriters or dealers to indemnify the Company, some or all of its directors and officers and its controlling persons, if any, for specified liabilities, which may include liabilities under the Securities Act of 1933, as amended, or the Securities Act. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Company&#8217;s restated certificate of incorporation, as amended, or the Charter, provides that to the fullest extent permitted by the DGCL, none of the Company&#8217;s directors shall be liable to the Company or its stockholders for monetary damages arising from a breach of fiduciary duty owed to the Company or its stockholders. In addition, the Company&#8217;s amended and restated by-laws, or the Bylaws, provide that the Company must indemnify its directors and officers to the fullest extent authorized by the DGCL and must also pay expenses incurred in defending any such proceeding in advance of its final disposition upon delivery of an undertaking, by or on behalf of an indemnified person, to repay all amounts so advanced if it should be determined ultimately that such person is not entitled to be indemnified under this section or otherwise. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Company has entered into indemnification agreements with each of our directors and executive officers in which we have agreed to indemnify, defend and hold harmless, and also advance expenses as incurred, to the fullest extent permitted under applicable law, from damage arising from the fact that such person is or was an officer or director of the Company or its subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, the Company&#8217;s Charter, the Company&#8217;s Bylaws, any agreement, any vote of stockholders or disinterested directors or otherwise. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Company expects to maintain standard policies of insurance that provide coverage (1) to its directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (2) to the Company with respect to indemnification payments that it may make to such directors and officers. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Company has purchased and intends to maintain insurance on behalf of Cartesian Therapeutics, Inc. and any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in that capacity, subject to certain exclusions and limits of the amount of coverage. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br></div></div></div>
<!--End Page 33-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 34-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_300-part-2_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-style: italic;">Exhibits</font><font style="font-weight: normal;"> </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 29pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 433pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 29pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description </div></td></tr><tr><td style="width: 29pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000110465916129891/a16-14002_1ex3d1.htm">3.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restated Certificate of Incorporation of Selecta Biosciences, Inc. (incorporated herein by reference to Exhibit&#160;3.1 of the Registrant&#8217;s Current Report on Form&#160;8-K (File No. 001-37798) filed on June&#160;29, 2016). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368722000109/exhibit31_charteramendment.htm">3.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Amendment to the Restated Certificate of Incorporation of Selecta Biosciences, Inc., dated June&#160;21, 2022 (incorporated herein by reference to Exhibit&#160;3.1 of the Registrant&#8217;s Current Report on Form&#160;8-K (File No. 001-37798) filed on June&#160;21, 2022). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex33.htm">3.3</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Amendment to the Restated Certificate of Incorporation of Selecta Biosciences, Inc., dated November&#160;13, 2023 (incorporated herein by reference to Exhibit&#160;3.3 of the Registrant&#8217;s Current Report on Form&#160;8-K (File No. 001-37798) filed on November&#160;13, 2023). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368724000048/exhibit32certificateofamen.htm">3.4</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Amendment to the Restated Certificate of Incorporation, as amended, of Cartesian Therapeutics, Inc., dated March&#160;28, 2024 (incorporated herein by reference to Exhibit&#160;3.2 of the Registrant&#8217;s Current Report on Form&#160;8-K (File No. 001-37798) filed on March&#160;28, 2024). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523276086/d549858dex32.htm">3.5</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated By-laws of Cartesian Therapeutics, Inc. (incorporated herein by reference to Exhibit&#160;3.2 of the Registrant&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-37798) filed on November&#160;13, 2023). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185dex34.htm">3.6</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Non-Voting Convertible Preferred Stock (incorporated herein by reference to Exhibit&#160;3.4 of the Registrant&#8217;s Current Report on Form&#160;8-K (File No. 001-37798) filed on November&#160;13, 2023). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000145368724000048/exhibit31certificateofamen.htm">3.7</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Amendment to the Certificate of Designation of Series&#160;A Non-Voting Convertible Preferred Stock, dated March&#160;26, 2024 (incorporated herein by reference to Exhibit&#160;3.1 of the Registrant&#8217;s Current Report on Form&#160;8-K (File No. 001-37798) filed on March&#160;28, 2024). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/ef20031962_ex3-1.htm">3.8</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non-Voting Convertible Preferred Stock (incorporated herein by reference to Exhibit&#160;3.1 of the Registrant&#8217;s Current Report on Form&#160;8-K (File No. 001-37798) filed on July&#160;2, 2024). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000104746916013398/a2228672zex-4_2.htm">4.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Specimen Certificate Representing Common Stock (incorporated herein by reference to Exhibit&#160;4.2 of the Registrant's Registration Statement on Form&#160;S-1 (File No. 333-211555) filed on May&#160;24, 2016). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/ef20031962_ex10-2.htm">4.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Registration Rights Agreement, dated as of July&#160;2, 2024, by and among the Registrant and the several purchasers party thereto (incorporated herein by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Current Report on Form&#160;8-K (File No. 001-37798) filed on July&#160;2, 2024). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20039376x3_ex5-1.htm">5.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of Covington &amp; Burling LLP. </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20039376x3_ex5-1.htm">23.1</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Covington &amp; Burling LLP (included in Exhibit&#160;5.1). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20039376x3_ex23-2.htm">23.2</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm. </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20039376x3_ex23-3.htm">23.3</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of BDO USA, P.C., independent registered public accounting firm. </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOA">24.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Powers of Attorney (incorporated by reference to the signature page hereto). </div></td></tr><tr><td style="width: 29pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20039376x3_ex107.htm">107</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 433pt; padding-top: 0.01pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filing Fee Table.</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 29pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 433pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 17.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-style: italic;">Undertakings</font> </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Filing Fee Tables&#8221; or &#8220;Calculation of Registration Fee&#8221; table, as applicable, in the effective registration statement; and </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-3<br></div></div></div>
<!--End Page 34-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 35-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_300-part-2_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">provided<font style="font-style: normal;">, </font>however<font style="font-style: normal;">, that paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is a part of the registration statement. </font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining liability under the Securities Act to any purchaser: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(A)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(B)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. <font style="font-style: italic;">Provided</font>, <font style="font-style: italic;">however</font>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-4<br></div></div></div>
<!--End Page 35-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 36-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_301-sig_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">SIGNATURES </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&#160;S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Frederick, Maryland, on December&#160;13, 2024. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 192pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 264pt;" colspan="7"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 192pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="7" style="width: 264pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CARTESIAN THERAPEUTICS, INC.</div></td></tr><tr><td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ CARSTEN BRUNN, PH.D. </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 192pt; padding-top: 1.76pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Carsten Brunn, Ph.D. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><font style="font-style: italic;">President and Chief Executive Officer</font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 192pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 60pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a name="tPOA"><!--Anchor--></a>POWER OF ATTORNEY </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of the undersigned officers and directors of the registrant hereby severally constitutes and appoints Carsten Brunn, Ph.D. and Blaine Davis, and each of them singly (with full power to each of them to act alone), as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for him or her and in his or her name, place and stead, and in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this registration statement and any other registration statement for the same offering that is to be effective under Rule&#160;462(b) of the Securities Act, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act, this registration statement has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SIGNATURE</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">TITLE</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DATE </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ CARSTEN BRUNN, PH.D.</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 180pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President, Chief Executive Officer and Director (Principal Executive Officer) </div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 84pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;13, 2024 </div></td></tr><tr><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Carsten Brunn, Ph.D.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ BLAINE DAVIS</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 180pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 84pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;13, 2024 </div></td></tr><tr><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Blaine Davis</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ CARRIE S. COX</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chairman of the Board</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;13, 2024</div></td></tr><tr><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Carrie S. Cox</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ TIMOTHY C. BARABE</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;13, 2024</div></td></tr><tr><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Timothy C. Barabe</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ NISHAN DE SILVA, M.D.</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;13, 2024</div></td></tr><tr><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Nishan de Silva, M.D.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ MURAT KALAYOGLU, M.D., PH.D.</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;13, 2024</div></td></tr><tr><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Murat Kalayoglu, M.D., Ph.D.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ KEMAL MALIK, MBBS</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;13, 2024</div></td></tr><tr><td style="width: 180pt; padding-top: 1.76pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Kemal Malik, MBBS</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.76pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.76pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 84pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-5<br></div></div></div>
<!--End Page 36-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 37-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20039376x3_s3_301-sig_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SIGNATURE</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">TITLE</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DATE </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ MICHAEL SINGER, M.D., PH.D.</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;13, 2024</div></td></tr><tr><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Michael Singer, M.D., Ph.D.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ TIMOTHY SPRINGER, PH.D.</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;13, 2024</div></td></tr><tr><td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Timothy Springer, Ph.D.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/S/ PATRICK ZENNER</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;13, 2024</div></td></tr><tr><td style="width: 180pt; padding-top: 1.76pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Patrick Zenner</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 180pt; padding-top: 1.76pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.76pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 84pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-6<br></div></div></div>
<!--End Page 37-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ny20039376x3_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.11.1.5268
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  <div style="text-align: right;"><font style="font-weight: bold;"> Exhibit 5.1</font><br>
  </div>
  <div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z00725a4f6bec4cc2b3a040c00a7157d6" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 78%;">
              <div>
                <div style="text-align: left;">
                  <div style="text-align: right;">
                    <div>
                      <div style="text-align: left;"><img src="ny20039376x3_ex5-1logo01.jpg"></div>
                    </div>
                  </div>
                </div>
              </div>
            </td>
            <td style="width: 22%;">
              <div>
                <div style="text-align: left;">
                  <div>
                    <div>
                      <div>Covington &amp; Burling LLP<br>
                      </div>
                      <div>The New York Times Building<br>
                        620 Eighth Avenue<br>
                      </div>
                      <div>New York, NY 10018-1405<br>
                      </div>
                      <div>T +1 212 841 1000</div>
                    </div>
                  </div>
                </div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: right; margin-left: 324pt;">December 13, 2024</div>
    <div style="text-align: right; margin-left: 324pt;"> <br>
    </div>
    Cartesian Therapeutics, Inc.
    <div>7495 New Horizon Way</div>
    <div>Frederick, Maryland 21703</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Ladies &amp; Gentlemen:</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">We have acted as counsel to Cartesian Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-style: italic;">Company</font>&#8221;), in connection with the registration by the Company under the Securities Act of
      1933, as amended (the &#8220;<font style="font-style: italic;">Act</font>&#8221;), of the resale of up to (i) 5,813,223 shares (the &#8220;<font style="font-style: italic;">Issued Shares</font>&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;<font style="font-style: italic;">Common Stock</font>&#8221;), and (ii) 437,927 shares (the &#8220;<font style="font-style: italic;">Underlying Shares</font>&#8221;) of the Company&#8217;s Common Stock issuable upon the conversion of 437,927 shares (the &#8220;<font style="font-style: italic;">Preferred Shares</font>&#8221;) of the Company&#8217;s Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share, pursuant to the registration statement on Form S-3 filed with the Securities and Exchange
      Commission (the &#8220;<font style="font-style: italic;">Commission</font>&#8221;) on the date hereof (such registration statement, as amended to the date hereof, is herein referred to as the &#8220;<font style="font-style: italic;">Registration Statement</font>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">We have reviewed such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion.&#160; We have assumed that all signatures
      are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Based upon the foregoing, we are of the opinion that the Issued Shares have been duly authorized and validly issued and are fully paid and non-assessable, and the Underlying Shares initially issuable upon conversion of
      the Preferred Shares have been duly authorized and reserved for issuance, and, when the Preferred Shares have been duly converted into the Underlying Shares in accordance with the terms of the Preferred Shares, the Underlying Shares will be validly
      issued, fully paid and non-assessable.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">We are members of the bar of the State of New York.&#160; We do not express any opinion herein on any laws other than the Delaware General Corporation Law.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><img src="ny20039376x3_ex5-1logo02.jpg"></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement.&#160; We also hereby consent to the reference to our firm under the heading &#8220;Legal Matters&#8221;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>in the prospectus constituting part of the Registration Statement.&#160; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the
      Act.</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z08cbc9921492475db394d8d68fcabeb1" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 70%;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%;" rowspan="1" colspan="2">
              <div style="text-align: right; margin-left: 9pt;">&#160;Very truly yours,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 70%;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%;">
              <div>&#160;</div>
            </td>
            <td style="width: 10%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 70%;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%;" rowspan="1" colspan="2">
              <div style="text-align: right;">&#160;/s/ Covington &amp; Burling LLP</div>
            </td>
          </tr>

      </table>
    </div>
    <br>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>ny20039376x3_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.11.1.5268
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 23.2</font><br>
    </div>
    <div><font style="font-weight: bold;"> </font><br>
      <div style="text-align: center; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
      <div>&#160;</div>
      <div style="text-align: justify;">We consent to the reference to our firm under the caption &#8220;Experts&#8221; in the Registration Statement (Form S-3) and related Prospectus of Cartesian Therapeutics, Inc. for the registration of 6,251,150 shares of its
        common stock and to the incorporation by reference therein of our reports dated March 7, 2024, with respect to the consolidated financial statements of Cartesian Therapeutics, Inc. and the effectiveness of internal control over financial reporting
        of Cartesian Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.</div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div>/s/ Ernst &amp; Young LLP</div>
      <div>&#160;</div>
      <div>Boston, Massachusetts</div>
      <div>&#160;</div>
      <div>December 13, 2024</div>
      <div> <br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>4
<FILENAME>ny20039376x3_ex23-3.htm
<DESCRIPTION>EXHIBIT 23.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.11.1.5268
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="color: rgb(0, 0, 0);"></font>
  <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Exhibit 23.3</div>
  <div style="color: rgb(0, 0, 0);"><br>
  </div>
  <div style="text-align: center; color: rgb(0, 0, 0);"><u>Consent of Independent Auditor</u></div>
  <div style="color: rgb(0, 0, 0);"><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">We hereby consent to the incorporation by reference in the
      Prospectus constituting a part of this Registration Statement of Cartesian Therapeutics, Inc. (formerly known as Selecta Biosciences, Inc.) of our report dated January 23, 2024, relating to the financial statements of Cartesian Therapeutics, Inc., appearing in Cartesian Therapeutics, Inc.&#8217;s (formerly known as Selecta Biosciences, Inc.) Current Report on Form 8-K/A filed January 23, 2024.</font></div>
  <div style="color: rgb(0, 0, 0);"><br>
  </div>
  <div style="text-align: justify; color: rgb(0, 0, 0);">We also consent to the reference to us under the caption &#8220;Experts&#8221; in the Prospectus.</div>
  <div style="color: rgb(0, 0, 0);"><br>
  </div>
  <div style="text-align: justify; color: rgb(0, 0, 0);">/s/ BDO USA, P.C.</div>
  <div style="text-align: justify; color: rgb(0, 0, 0);">Potomac, Maryland</div>
  <div style="color: rgb(0, 0, 0);">&#160;</div>
  <div style="text-align: justify; color: rgb(0, 0, 0);">December 13, 2024</div>
  <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif;"> <font style="font-family: 'Times New Roman';"><br>
    </font></div>
  <div style="color: rgb(0, 0, 0);">&#160;</div>
  <font style="color: rgb(0, 0, 0);"></font>
  <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
</body>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>ny20039376x3_ex107.htm
<DESCRIPTION>EXHIBIT 107
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.11.1.5268
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 107</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Calculation of Filing Fee Tables</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Form S-3</div>
      <div style="text-align: center;">(Form Type)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Cartesian Therapeutics, Inc.</div>
      <div style="text-align: center;">(Exact Name of Registrant as Specified in its Charter)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Table 1: Newly Registered Securities</div>
      <div> <br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" id="z10542ce1e09c44319e11c9d63636f5a8" class="cfttable" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="vertical-align: bottom; width: 13%; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Security</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Type</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="2" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Security</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Class</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="2" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Fee</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Calculation</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Rule</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="2" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Amount</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Registered</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="2" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Proposed</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Maximum</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Offering</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Price Per</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Share</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="2" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Maximum</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Aggregate</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Offering</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Price</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="2" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Fee</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Rate</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="2" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Amount of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Registration</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Fee</div>
            </td>
            <td style="vertical-align: bottom; width: 2%; border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 13%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0);">Fees to Be Paid</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0);">Equity</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="2" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0);">Common stock,</div>
              <div style="text-align: center; color: rgb(0, 0, 0);">par value</div>
              <div style="text-align: center; color: rgb(0, 0, 0);">$0.0001 per share(1)</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="2" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0);">Rule 457(c)</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">
              <div style="color: rgb(0, 0, 0);">6,251,150(2</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">
              <div style="color: rgb(0, 0, 0);">20.89(3</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">$</div>
              </div>
            </td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">
                  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br>
                  </div>
                  <div style="font-family: 'Times New Roman',Times,serif;">130,586,523.50(3</div>
                </div>
              </div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">)</div>
              </div>
            </td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);">0.0001531</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);">19,992.80</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);"><br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; width: 13%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0);">Fees</div>
              <div style="text-align: center; color: rgb(0, 0, 0);">Previously</div>
              <div style="text-align: center; color: rgb(0, 0, 0);">Paid</div>
            </td>
            <td style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" class="cftguttercell" rowspan="1">&#160;&#160;
              <div style="color: rgb(0, 0, 0);">N/A</div>
            </td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0);">N/A</div>
            </td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0);">N/A</div>
            </td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0);">N/A</div>
            </td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0);">N/A</div>
            </td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0);">N/A</div>
            </td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0);">N/A</div>
            </td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0);">N/A</div>
            </td>
            <td style="vertical-align: bottom; width: 2%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 13%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="13" valign="bottom">
              <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Total Offering Amounts</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom"> 130,586,523.50<br>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);"><br>
              </div>
            </td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">
              <div style="color: rgb(0, 0, 0);">19,992.80<br>
              </div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);"><br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; width: 13%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="13" valign="bottom">
              <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Total Fees Previously Paid</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);">&#8212;</div>
            </td>
            <td style="vertical-align: bottom; width: 2%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 13%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="13" valign="bottom">
              <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Total Fee Offsets</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" nowrap="nowrap" valign="bottom">
              <div style="color: rgb(0, 0, 0);">&#8212;</div>
            </td>
            <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" nowrap="nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; width: 13%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="13" rowspan="1" valign="bottom">
              <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Net Fee Due</div>
            </td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" rowspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" rowspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" rowspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" rowspan="1" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" rowspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="text-align: right; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell" rowspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
            <td style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell" rowspan="1" nowrap="nowrap" valign="bottom">$ <br>
            </td>
            <td style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell" rowspan="1" nowrap="nowrap" valign="bottom">19,992.80</td>
            <td style="vertical-align: bottom; width: 2%; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell" rowspan="1" nowrap="nowrap" valign="bottom"><br>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div>
        <table class="DSPFListTable" id="z0c0e83000ca343d9aba774c5d39fa08f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" cellpadding="0" cellspacing="0">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 9pt;">
                <div style="text-align: left;"><font style="color: rgb(0, 0, 0);">(1)</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: rgb(0, 0, 0);">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this registration statement also covers such an indeterminate amount of shares of common stock, par value
                    $0.0001 per share (&#8220;Common Stock&#8221;), as may become issuable to prevent dilution resulting from stock splits, stock dividends and similar events.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table class="DSPFListTable" id="zbfc625c188d54e07be1e2cb338ac7c8b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" cellpadding="0" cellspacing="0">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 9pt;">
                <div style="text-align: left;"><font style="color: rgb(0, 0, 0);">(2)</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: rgb(0, 0, 0);">The amount registered consists of up to (i) 5,813,223 shares of Common Stock, and (ii) 437,927 shares of Common Stock issuable upon the conversion of 437,927 shares of Series B Non-Voting Convertible
                    Preferred Stock, par value $0.0001 per share.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table class="DSPFListTable" id="za0c6aba9db2843ec9671f4394022b8c4" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" cellpadding="0" cellspacing="0">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 9pt;">
                <div style="text-align: left;"><font style="color: rgb(0, 0, 0);">(3)</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: rgb(0, 0, 0);">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the shares of Common Stock on the Nasdaq Global Market on December 12, 2024
                    (such date being within five business days of the date that this registration statement was first filed with the Securities and Exchange Commission, in accordance with Rule 457(c) under the Securities Act).</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo_cartesian.jpg
<TEXT>
begin 644 logo_cartesian.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MX=]>$/\ HKO[5G_B9W[4G_SSZ/J.2?\ 0XK=/^8'T_ZB/-_CVU/K&-_Z!/\
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M2?\ SSZ/J.2?]#BMT_Y@?3_J(\W^/;4^L8W_ *!/_)EY>?K^'F?H!_:.G_\
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MN8UOO _P]UV*YT/0M'D*M+:WGCC3=9U74()(6N?#?A^6.6WE_(OP9_P<'?\
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ME=M*[['WQJO_ "#-0_Z\KK_T2]?GW^P1_P AW]L7_L[WXH?^HU\.:^%O&O\
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M'_$*]_P34_Z&O]JC_P .CX%_^=+7])U%?B/^MO$O_0ZQW_@W_@'O_5<-_P!
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MY([N: W<GL?QO_X)L_L&_M$^';SPW\5OV3_@?K,-W"8$UW1_ &@>#O&FFKC
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MC3O WQAU3]SX.\1^'H)W>/2U\6ZB(?"/B2VLA;PZK)J6BZG>^;-H5L#^I_\
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M*\0^%M;U;PYKVEWD3P7>FZSHE_<:9JEA=02JDL-Q9WUK/;S12(KQR1LCJ&!
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M9=E7YOAC)K#**ZC.="3M[3WX7_F2M*/JXI-?X6?TBT445^)'OA1110 4444
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M^T'7^+YH7_(<T;_L*Z=_Z5PU_M!U]QXK[Y#Z9G^>7G#DWP5_\5/\I!1117Y
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M"X:FY*%2%6-IPI1E&TZ<9:-;=C6E@,-1J1J4X24XWLW.3W33T;:V;"OX+_\
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M[.K^-W_J?:W7]!__  :*?\E6_;9_[)[\&?\ U)/'M?T/Q)_R0=?_ +%F6?\
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M_C3X%Z_JL46IW,\,0^V:[\.+R]^SGQMX6D=9)F%@)=;T"-DA\0V%JCV=]?\
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M;'PUXKM)IQ VJ7E_XB%NDSZ3>S'^][X&? OX4?LV?"OPA\%O@GX,TGP#\-O
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MG:0L?UW_ .#>_P#X*)?"/]@G]J+QWI_Q\U$>%_A+\?O!ND^$=6^(!LKZ_M_
MOBCPOJEUJWA75-:M]-@N[[_A&M0&I:QHVJ7-I97+Z?=7VE:G=>1I=EJ,\?\
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M[74X])\1Z[IM^^GW,]G=PV]ZMN;:::UN8XY&>"55X?\ X;>_8N_Z.\_9?_\
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MA@^IEETU/B'\0?"7@IM09069;)?$FKZ8;LJJLS" 2$!23P#7!A,=F^#J5J6
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M2E;V,6F[+F:=UKHDTD?NSX<_Y%[0?^P-I?\ Z0P5_-=_P3;^%/P]^.7[;_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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7E*4K+17;LM!QC&*M&*BELHI)+Y+0_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ny20039376x3_ex5-1logo01.jpg
<TEXT>
begin 644 ny20039376x3_ex5-1logo01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !4 5 # 2(  A$! Q$!_\0
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MVF\M5)Z13MP!D[)MRG[S$?4?_!'K_DS]/^Q@OOY14 ?;]%%% !1110 4444
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M9?/,$<"K&9-X??M QNW@-GKD9ZU\J?%+]H7Q_P#"_P")&NV,_FWOAOP;=_\
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M3PLKSQRSQQ*OEC=*Y;:N8P"W(J]\./%7Q OH/A5I'B"QU[3M7T?Q/>Z/KYO
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H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ny20039376x3_ex5-1logo02.jpg
<TEXT>
begin 644 ny20039376x3_ex5-1logo02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  6 '\# 2(  A$! Q$!_\0
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MA^TYX,_9?\'VVM^*Y+JYNM0F^RZ7H^FQ>;>:A/C.R),@8&1EB0!D#JR@\%\
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E 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
